Similar articles

• Pathogenesis of primary hepatocellular carcinoma.

  Curry GW, Beattie AD. Curry GW, et al. Eur J Gastroenterol Hepatol. 1996 Sep;8(9):850-5. Eur J Gastroenterol Hepatol. 1996. PMID: 8889449 Review.
• Clinical features, etiology, and survival of hepatocellular carcinoma among different countries.

  Omata M, Dan Y, Daniele B, Plentz R, Rudolph KL, Manns M, Piratvisuth T, Chen DS, Tateishi R, Chutaputti A. Omata M, et al. J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S40-9. doi: 10.1046/j.1440-1746.17.s1.14.x. J Gastroenterol Hepatol. 2002. PMID: 12000592 No abstract available.
• Cellular and molecular mechanisms of hepatocellular carcinoma: an update.

  Aravalli RN, Cressman EN, Steer CJ. Aravalli RN, et al. Arch Toxicol. 2013 Feb;87(2):227-47. doi: 10.1007/s00204-012-0931-2. Epub 2012 Sep 25. Arch Toxicol. 2013. PMID: 23007558 Review.
• Junctional structures and hepatocellular carcinoma: from the lab to the clinic?

  Vinken M, Vanhaecke T, Rogiers V. Vinken M, et al. Liver Int. 2008 Apr;28(4):432-4. doi: 10.1111/j.1478-3231.2008.01707.x. Liver Int. 2008. PMID: 18339070 No abstract available.
• Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.

  Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, Mazzolini G. Garcia MG, et al. Mol Pharm. 2011 Oct 3;8(5):1538-48. doi: 10.1021/mp200137c. Epub 2011 Aug 19. Mol Pharm. 2011. PMID: 21770423